Version July 2025
| Generic compound | ADF mechanism | Dosages available | Deterrence label* | Comments |
| Oxycodone | ||||
| OxyContin (oxycodone extended-release) and abuse-deterrent generic equivalent | Difficult to crush and if dissolved, the tablet forms a viscous gel that is difficult to inject IV. | Tablets: 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg, 80 mg | IV, nasal | |
| Xtampza ER (oxycodone extended-release) | Capsules contain microspheres of oxycodone and inactive ingredients that hinder dosage dumping via intranasal and oral misuse. Microspheres cannot be readily dissolved and will solidify within a needle to prevent injection. | Capsules: 9 mg, 13.5 mg, 18 mg, 27 mg, 36 mg | IV, nasal, oral | A good option for patients unable to swallow tablets. The capsules can be opened so that the microspheres may be safely poured into a feeding tube, sprinkled onto food, or placed directly into the mouth. Dosage expressed as oxycodone base; 9 mg base is equivalent to 10 mg oxycodone hydrochloride. |
| Targin (oxycodone extended-release plus naloxone) | Contains naloxone (opioid antagonist) which is not active when taken orally, but blocks opioid associated euphoria when injected or inhaled. | Tablets: 5/2.5 mg, 10/5 mg, 20/10 mg, 40/20 mg | IV, nasal | Available in Canada and other countries, not available in the United States. |
| Roxybond (oxycodone immediate-release) | Difficult to crush and if dissolved, the tablet forms a viscous gel that is difficult to inject IV. | Tablets: 5 mg, 10 mg, 15 mg, 30 mg | IV, nasal | |
| Hydrocodone | ||||
| Hysingla ER (hydrocodone extended-release tablet) and abuse-deterrent generic equivalent | Difficult to crush and if dissolved, the tablet forms a viscous gel that is difficult to inject IV. | Tablets: 20 mg, 30 mg, 40 mg, 60 mg, 80 mg, 100 mg, 120 mg | IV, nasal, oral | |
ADF: abuse-deterrent formulation; ER: extended release; FDA: Food and Drug Administration; IV: intravenous.
* The type of potential abuse deterred according to the drug label.
